The tech company estimates that its investment will create 100,000 jobs focused on AI and emerging technologies. Canal+'s shares fell on the London Stock Exchange and Havas's stock rose on Euronext ...

Investors' focus could, however, shift back onto the possible market impacts of GLP-1 agonists in 2025, particularly as a result of a major expansion of current supplies after Novo Nordisk was given a ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 496.78% and ...

Novo Nordisk's Wegovy and Ozempic and Eli Lilly's Zepbound and Mounjaro have been shown to lead to average weight loss of at ...

On the other hand, the nature of its industry means that there will often be solid new reasons to be a bit more cautious ...

Eli Lilly (LLY 0.86%) and Novo Nordisk (NVO -1.53%) have competed for decades. They're both leaders in the areas of insulin ...

Over 18 months, people taking Zepbound lost more weight on average than those on Wegovy, according to the first head-to-head ...

For the first time in a decade, obesity in the U.S. is declining — and a new study suggests it’s because of wildly popular ...

We recently compiled a list of the 16 Best Income Stocks To Buy According to Analysts. In this article, we are going to take ...

NVO's CagriSema target of up to 25% in long-term weight loss is highly promising vs. 15% through Wegovy and 20% through ...

Eli Lilly, the pharma giant behind the popular weight-loss drug Zepbound, said it plans to test obesity medications as a ...